IN DEVELOPMENT
DUR-928
An endogenous, orally bioavailable small molecule in development for chronic liver disease and acute organ injury.
LEARN MORE
REMOXY® (ORADUR®-Oxycodone) ER capsules
An investigational drug candidate containing oxycodone in extended-release capsules, whose ability to deter common methods of abuse is under study. Oxycodone exposes users to risks of addiction, abuse, and misuse even where abuse-deterrent properties exist. REMOXY ER is not currently authorized by the FDA for marketing in the U.S. for any indication.
LEARN MORE
POSIMIR®
(SABER®-Bupivacaine)
An investigational non-opioid, locally-acting analgesic being evaluated for its ability to deliver 3 days of continuous pain relief after surgery.
LEARN MORE
ORADUR®-Methylphenidate ER
An investigational once-daily formulation of the widely-prescribed ADHD medication methylphenidate under evaluation for resistance to common methods of tampering.
LEARN MORE
Sustained-release Ophthalmology Product
An investigational sustained-release ophthalmology product incorporating DURECT’s SABER depot technology.
LEARN MORE